Low molecular weight heparin for acute ischemic heart disease.
LMWH seems to me to be an attractive antithrombotic therapy that can be used in combination with antiplatelet treatment in patients with acute coronary syndromes. One of the advantages of LMWH is that home treatment becomes a possibility since the agent can be administered as subcutaneous injection without monitoring coagulation times. Therefore, in some patients, once they are stabilized and past the acute event, outpatient subcutaneous treatment with LMWH could be an attractive alternative to impatient treatment with intravenous heparin.
Conti
C R
CR
D000208:Acute Disease; D000925:Anticoagulants / Q000008:administration & dosage / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D017985:Dalteparin / Q000008:administration & dosage / Q000627:therapeutic use; D004333:Drug Administration Routes; D004562:Electrocardiography; D006495:Heparin, Low-Molecular-Weight / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D017202:Myocardial Ischemia / Q000188:drug therapy* / Q000503:physiopathology; D017762:Nadroparin / Q000008:administration & dosage / Q000627:therapeutic use
D000925:Anticoagulants; D006495:Heparin, Low-Molecular-Weight; D017762:Nadroparin; D017985:Dalteparin